We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Comparison of Montelukast and Fexofenadine for Chronic Idiopathic Urticaria

Eustachio Nettis, MD; Porzia Dambra, MD; Lucia D'Oronzio, MD; Maria Paola Loria, PhD; Antonio Ferrannini, MD; Alfredo Tursi, MD
Arch Dermatol. 2001;137(1):99-100. doi:.
Text Size: A A A
Published online


Chronic idiopathic urticaria (CIU) is a troublesome disorder with anunknown etiological agent. Mast cell activation and release of mediators occurin all forms of urticaria. Although histamine is the principal inflammatorymediator of mast cell derivation, other mediators are freed after mast cellactivation such as cysteinyl leukotrienes (leukotrienes C4, D4, and E4).1 We evaluatethe efficacy and tolerability of an antileukotriene drug, montelukast sodium,2 in relation to fexofenadine hydrochloride, an antihistaminicdrug, in patients affected by CIU.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

This model of variance analysis shows that the reduction of symptomsis highly significant at later times of observation (Friedman test, 72.56; P<.001). The total symptom scores of the patients treated with fexofenadinewere on the average worse than those obtained from the montelukast-treatedpatients (Kruskal-Wallis, 8.18; P<.005), although the reductionin the time of the symptomatic profile is essentially the same for both drugs(the interaction between treatment and time of observation is not significant).t0 Indicates the time of measurement as before treatment began;t1, 10 days after treatment began; t2, 20 days aftertreatment began; and t3, 30 days after treatment began.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

35 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles